Trial Profile

An International, Randomized, Double-blind Study Evaluating the Efficacy and Safety of Fondaparinux Versus Enoxaparin in the Acute Treatment of Unstable Angina/Non ST-segment Elevation MI Acute Coronary Syndromes.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 20 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fondaparinux sodium (Primary) ; Enoxaparin sodium
Indications Acute coronary syndromes; Embolism and thrombosis; Myocardial infarction; Unstable angina pectoris
Focus Therapeutic Use
Acronyms OASIS-5
Sponsors GlaxoSmithKline; GSK

10 May 2011 Actual initiation date (Apr 2003) added as reported by ClinicalTrials.gov.
10 May 2011 Actual end date (Dec 2005) added as reported by ClinicalTrials.gov.
10 May 2011 Additional lead trial centres identified as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com